[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-aneurysm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-aneurysm":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,54,85,110,136,163,185,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100603938","the-use-of-p4864-mw-hpc-flow-modulation-device-in-the-treatment-of-wide-necked-intracranial-aneurysms-100603938",false,"NCT07143019","The Use of p48\u002F64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms","p48\u002F64 MW HPC in Aneurysm Occlusion (PIANO): Prospective, Multicenter, Single-arm Clinical Trial to Determine Safety and Effectiveness of the Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms.","PIANO","Inclusion Criteria:\n\n1. Subject is ≥ 18 years\n2. Subject has a mRS ≤2 before the index procedure\n3. Subject has an unruptured or recanalized intracranial aneurysm (IA). The subject may also have a previous ruptured aneurysm, provided rupture of this aneurysm has occurred more than 30 days from the index procedure. The IA must have the following characteristics below:\n\n   1. Saccular or fusiform morphology\n   2. Located in the internal carotid artery and its branches\n   3. Aneurysm neck ≥4 mm or dome-to-neck ratio \\\u003C2\n   4. Parent vessel diameter ≥2.0mm and ≤5.0mm both distal and proximal to the target IA\n4. Subject or subject's legally authorized representative (LAR) has provided written informed consent and has agreed to comply with study procedures.\n\nExclusion Criteria:\n\n1. Previous flow diverter or stent within the parent vessel of the target aneurysm to be treated\n2. Any other known IA requiring treatment within 3 months post-procedure\n3. Subarachnoid hemorrhage in the past 30 days prior to the index procedure\n4. Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular) located at the point of vessel bifurcation\n5. Anatomy unsuitable for endovascular procedure due to severe vessel tortuosity or stenosis, or stented ipsilateral carotid artery within 3 months prior to the index procedure\n6. Subject with a brain arteriovenous malformation (AVM) or other vascular malformation in the area of the target aneurysm\n7. Major surgery in the last 30 days, including endovascular procedures, or is planned in the next 90 days after enrollment date\n8. Unstable neurologic deficit (i.e., any worsening of clinical condition in the last 30 days)\n9. Known serious sensitivity to radiographic contrast agents that cannot be managed medically\n10. Known sensitivity to nickel, titanium metals or their alloys or any other investigational device components\n11. Irreversible bleeding disorder and\u002For signs of active bleeding at subject presentation\n12. Known renal failure with a serum creatinine \\>2.5 mg\u002Fdl (or 220 μmol\u002Fl) not on dialysis\n13. Contraindication to CT scan, MRI, or angiography\n14. Contraindication or known allergies to anticoagulants or antiplatelets (e.g. aspirin, heparin, clopidogrel, prasugrel, or ticagrelor)\n15. Known coagulopathy, or an admission International Normalized Ratio \\>3.0 without oral anticoagulation therapy, or an admission platelet count of \\\u003C100000\n16. Has acute life-threatening illness other than the neurological disease (i.e., acute kidney or heart failure) to be treated in this trial\n17. Unable to complete the required study follow-ups\n18. Evidence of active infection at the time of treatment (e.g., fever, elevated white blood cell count)\n19. Participating in another clinical trial that could affect participation or primary outcomes of this study\n20. Women currently pregnant or wish to become pregnant during the study or breast feeding.","ALL","18 Years",{"count":20,"type":21},214,"ESTIMATED","INTERVENTIONAL",[24],"NA","To determine safety and effectiveness of the p48 MW HPC and p64 MW HPC Flow Modulation Device in the treatment of wide-necked intracranial aneurysms.",[27,28,29,30,31],"Hemorrhagic Stroke","Aneurysm, Intracranial","Saccular Aneurysm","Fusiform Aneurysm","Brain Aneurysm",[33,34,35,36,37,38,39,40],"Neurovascular Intervention","phenox","Brain","Unruptured Aneurysm","Flow diversion","Flow diverter","Occlusion","Flow modulation device","RECRUITING","2026-06-22",{"date":44,"type":45},"2026-06-25","ACTUAL",{"date":47,"type":45},"2026-03-16",{"date":49,"type":21},"2032-07",{"name":51,"class":52},"phenox Inc.","INDUSTRY",21,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100569066","multimodal-biocollection-linked-to-the-french-register-of-intracranial-aneurysms-100569066","NCT06689410","Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms","bCAN","Inclusion criteria for sporadic ICA cases:\n\n* Any adult patient consulting for a definite and typical bifurcation AIC authenticated on MRI and\u002For cerebral arteriography\n* Aneurysm discovered less than a year ago, with initial imaging (MRI and\u002For CTA and DSA) available\n* Written consent obtained for study participation\n* Patient covered by a social security plan\n\nInclusion criteria for index and related cases (familial forms) of intracranial aneurysms (ICA):\n\n* Index case: Any adult patient consulting for a definite and typical bifurcation ICA presenting at least one other case with ICA related (child, parent, brother, sister) detected by MRI with at least one Time of Flight (TOF) sequence.\n* Family relatives: children, parents, brothers, sisters, of legal age, of patients with a family history of definite, typical bifurcation AIC (≥ 4 affected), Screening to be performed using MRI with at least a Time of Flight (TOF) sequence.\n* Written consent to participate in the study\n* Patient and relatives covered by a social security plan\n\nExclusion Criteria:\n\n* Syndromic diagnosis known to cause ICA: Marfan syndrome, OSA with SMAD 3, Elhers Danlos syndrome type II and IV, Autosomal Dominant Cystic Fibrosis, Moya-Moya syndrome\n* AIC with : Dissecting or fusiform, Associated with arteriovenous malformation, Blister-like, Mycotic\n* Cerebral white matter pathology detected on MRI evoking : Col4a1 mutation\n* Patient under guardianship or conservatorship\n* Person under court protection\n* Contraindication to an MRI scan",{"count":62,"type":21},1100,[24],"The purpose of the bCAN study is to create a prospective collection of multimodal data and human samples, linked to the French Intracranial Aneurysm Registry (FRAN).\n\nThe aim of bCAN is to enable risk stratification of ruptured ICAs by redefining \"intracranial aneurysm disease\". The description of genotypically and phenotypically specific subgroups of cases will pave the way for improved patient management based on new diagnostic\u002Fprognostic strategies among AIC carriers, either in a familial context, or at the level of the general population.",[66,31,67],"Aneurysm","Congenital Disease",[69,70,71,72,73],"intracranial aneurysm","phenotype","genetics","imaging","multimodal data","2026-05-26",{"date":76,"type":45},"2026-05-29",{"date":78,"type":45},"2025-03-25",{"date":80,"type":21},"2027-03-25",{"name":82,"class":83},"Nantes University Hospital","OTHER",26,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100577472","post-market-registry-study-of-intracranial-aneurysms-treated-with-sugita-clipping-devices-100577472","NCT06798740","Post Market Registry Study of Intracranial Aneurysms Treated With Sugita Clipping Devices","T2_PMCF","Inclusion Criteria:\n\n* Subject has an intracranial aneurysm (ruptured or unruptured) that can be treated with one of the proposed devices.\n* Subject is adult, ≥18 years.\n* As per national regulations, subject or subject's legally authorized representative (LAR) has signed written informed consent.\n* Subject is willing to comply with scheduled visits and examinations per institutional standard of care.\n\nExclusion Criteria:\n\n* Subject is currently enrolled in or plans to be enrolled in a concurrent drug or device randomized study.\n* Subject has a condition which will not allow him\u002Fher to comply with his\u002Fher post-procedure follow up per the institutional standard of care (medical condition, subject living abroad and unable to return for follow- up, e.g.).\n* Subject does not meet IFU criteria of the subject device.\n* Subject is a child, \\\u003C18 years.",{"count":93,"type":21},150,"OBSERVATIONAL","The objective of this study is to verify the performance and safety of the Sugita Aneurysm Clips devices when used as intended and to identify possible risk factors. Data collected will be used to support the continuing performance and safety of the devices in the post-market use environment in Europe. Subjects who have an intracranial aneurysm that the physician intends to treat with the subject devices will be included in the study. Subjects will be followup as per hospital standard of care for 5 years.",[31],[98,99],"clip","sugita","2026-02-05",{"date":102,"type":45},"2026-02-09",{"date":104,"type":45},"2025-04-14",{"date":106,"type":21},"2033-02-14",{"name":108,"class":83},"Mizuho Corporation",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":109},"100612856","lumens-1-canada-early-feasibility-study-clinical-investigation-plan-100612856","NCT07259018","LUMENS-1 Canada Early Feasibility Study Clinical Investigation Plan","A Single-arm, Open Label, Single-center Early Feasibility Study of the LuSeed Aneurysm Embolization System in Individuals With Unruptured Intracranial Aneurysms.","Inclusion Criteria:\n\n1. Patients indicated for treatment of unruptured intracranial aneurysms (IA) according to AHA \u002F ASA Guidelines.\n2. Age 18-80 years at screening\n3. Patients who are suitable for non-emergency endovascular embolization of saccular IAs\n4. The IA must have had the following characteristics:\n\n   * IA located in bifurcation in the anterior or posterior circulation\n   * IA dimensions appropriate for treatment with LuSeed- Vascular Embolization Device per implant size selection guidelines as outlined in the Instructions for\n\n   Use (IFU) and as follows:\n   * IA Width: 2.5-5.5\\[mm\\]\n   * IA Neck: 2.0-5.0\\[mm\\]\n   * IA Height: min 4.0 \\[mm\\]- device short configuration, min 5.0 \\[mm\\]-device long configuration • The AI must meet the definition of a \"wide-neck\" aneurysm.\n5. Patient is willing and able to participate in the study for the duration of the study follow-up and can comply with study requirements\n6. Patient able to give their informed consent can be included in this study.\n\nExclusion Criteria:\n\n1. Ruptured intracranial aneurysm\n2. Patient anatomy or physiology considered unsuitable for endovascular treatment as determined by imaging Core Lab\n3. Contraindication for arterial access\n4. Intracranial aneurysm neck diameter less than 2mm or greater than 5 mm\n5. Intracranial aneurysm sac diameter less than 2.5mm or greater than 5.5mm\n6. Intracranial aneurysm minimum height less than 4.0 mm\n7. Target Intracranial aneurysm contains other devices\u002Fimplants (e.g., coils)\n8. Stenosis of the target IA's parent vessel \\>50%\n9. Known allergy to platinum, nickel, or titanium\n10. Known allergy to contrast agents\n11. Absolute contraindication to anticoagulation or antiplatelet therapy\n12. Anticoagulation medications such as warfarin that cannot be discontinued\n13. Pregnant, breastfeeding or planning pregnancy within next 12 months\n14. Acute or chronic renal failure (stage III or IV by VARC-3 criteria)\n15. Cerebral embolism, stroke, or TIA in past 6 months\n16. Myocardial infarction in the past 6 months\n17. Any other medical issue within the brain that would preclude device implantation (such as brain surgery, radiation in the target area of intervention from an external beam source, acute traumatic craniocerebral injury, etc.)\n18. Patient had any circulatory, neurovascular, cardiovascular, or neurologic conditions that resulted in unstable neurological symptoms at screening.\n19. Patient had physical, neurologic or psychiatric conditions which precluded his\u002Fher ability to comply with all aspects of the screening, evaluation, treatment, and the postprocedure follow-up schedule.\n20. Other medical conditions that cause an inability to comply with study requirements and\u002For that could increase the risk of neurovascular procedures (e.g., extreme frailty, liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)\n21. Patient had a life expectancy of less than 12 months.\n22. Current participation in another study with investigational devices or drugs that would confound the effect of the study outcomes.","80 Years",{"count":119,"type":21},10,[24],"The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a single-arm, open-label, single-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. Up to 10 eligible subjects meeting inclusion and exclusion criteria and providing consent will be enrolled in a Canadian site.",[123,124,125,29,31],"Aneurysm Cerebral","Bifurcation","Unruptured Intracranial Aneurysm","NOT_YET_RECRUITING","2025-12-02",{"date":129,"type":45},"2025-12-09",{"date":131,"type":21},"2025-12",{"date":133,"type":21},"2028-05",{"name":135,"class":52},"LuSeed Vascular LTD.",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":117,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},"100574598","lumens-1-eu-efs-cip-100574598","NCT06761365","LUMENS-1 EU EFS CIP","A SINGLE-ARM, OPEN LABEL, MULTI-CENTER EARLY FEASIBILITY STUDY OF THE LUSEED ANEURYSM EMBOLIZATION SYSTEM IN INDIVIDUALS WITH UPRUPTURED INTRACRANIAL ANEURYSMS","Inclusion Criteria:\n\n* Patients indicated for treatment of unruptured intracranial aneurysms (IA) according to AHA \u002F ASA Guidelines.\n\n  1. Age 18-80 years at screening\n  2. Patients who are suitable for non-emergency endovascular embolization of saccular IAs\n  3. The IA must have had the following characteristics:\n* IA located in the anterior or posterior circulation\n* IA dimensions appropriate for treatment with\n\nLuSeed-Vascular Embolization Device per implant size selection guidelines as outlined in the Instructions for Use (IFU) and as follows:\n\n* IA Width: 2.5-5.5\\[mm\\]\n* IA Neck: 2.0-5.0\\[mm\\]\n* IA Height: min 4.0 \\[mm\\]- device short configuration, min 5.0 \\[mm\\]-device long configuration 4. Patient is willing and able to participate in the study for the duration of the study follow-up and can comply with study requirements Exclusion Criteria: 5. Patient able to give their informed consent can be included in this study. Exclusion Criteria\n\n  1. Ruptured intracranial aneurysm\n  2. Patient anatomy or physiology considered unsuitable for endovascular treatment as determined by imaging Core Lab\n  3. Contraindication for arterial access\n  4. Intracranial aneurysm neck diameter less than 2mm or greater than 5 mm\n  5. Intracranial aneurysm sac diameter less than 2.5mm or greater than 5.5mm\n  6. Intracarnial aneurysm minimum hight less than 4.0 mm\n  7. Target Intracranial aneurysm contains other devices\u002Fimplants (e.g., coils)\n  8. Stenosis of the target IA's parent vessel \\>50%\n  9. Known allergy to platinum, nickel, or titanium\n  10. Known allergy to contrast agents\n  11. Absolute contraindication to anticoagulation or antiplatelet therapy\n  12. Anticoagulation medications such as warfarin that cannot be discontinued\n  13. Pregnant, breastfeeding or planning pregnancy within next 12 months\n  14. Acute or chronic renal failure (stage III or IV by VARC-3 criteria)\n  15. Cerebral embolism, stroke, or TIA in past 6 months\n  16. Myocardial infarction in the past 6 months\n  17. Any other medical issue within the brain that would preclude device implantation (such as brain surgery, radiation in the target area of intervention from an external beam source, acute traumatic craniocerebral injury, etc.)\n  18. Patient had any circulatory, neurovascular, cardiovascular, or neurologic conditions that resulted in unstable neurological symptoms at screening.\n  19. Patient had physical, neurologic or psychiatric conditions which precluded his\u002Fher ability to comply with all aspects of the screening, evaluation, treatment, and the postprocedure follow-up schedule.\n  20. Other medical conditions that cause an inability to comply with study requirements and\u002For that could increase the risk of neurovascular procedures (e.g., extreme frailty, liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)\n  21. Patient had a life expectancy of less than 12 months .\n  22. Current participation in another study with investigational devices or drugs that would confound the effect of the study outcomes.",{"count":144,"type":21},30,[24],"The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a prospective, single-arm, open-label, multi-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. Up to 30 eligible subjects meeting inclusion and exclusion criteria and providing consent will be enrolled across a maximum of 10 medical centers in the EU.",[123,124,125,29,31],[124,149,150,151,152,153],"Embolization","Flow Diverter","Intrasaccular Device","Cerebral Aneurysm","Unruptured","2025-11-21",{"date":156,"type":45},"2025-11-26",{"date":158,"type":45},"2024-10-07",{"date":160,"type":21},"2027-06",{"name":135,"class":52},6,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":109},"100606435","safety-and-efficacy-of-aneurysms-treated-with-endovascular-devices-100606435","NCT07175519","Safety and Efficacy of Aneurysms Treated With Endovascular Devices","SEATED","Inclusion Criteria:\n\n* All patients undergoing endovascular aneurysm treatment.\n\nExclusion Criteria:\n\n* All endovascular patients NOT undergoing aneurysm treatment e.g. stents used for stroke treatment; devices and materials used for dAVF, AVM treatments.\n* Insufficient background data available e.g., to determine size of aneurysm and device.",{"count":171,"type":21},5000,"In this project the investigators study the safety and efficacy of the recent endovascular devices used in treatment of brain aneurysms.",[31,174,175],"Stroke","Intracranial Hemorrhages","2025-09-08",{"date":178,"type":45},"2025-09-16",{"date":180,"type":45},"2025-01-15",{"date":182,"type":21},"2035-01-15",{"name":184,"class":83},"King's College London",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":200,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":216},"100357638","the-rise-trial-a-randomized-trial-on-intra-saccular-endobridge-devices-100357638","NCT03936647","The RISE Trial: A Randomized Trial on Intra-Saccular Endobridge Devices","RISE","Inclusion Criteria:\n\n* patient with an intracranial aneurysm in whom WEB is considered an appropriate therapeutic option by the participating clinician\n* aneurysm of maximum diameter of 4-11 mm\n* may include (but are not restricted to) saccular bifurcation aneurysms of the middle cerebral artery, basilar bifurcation, carotid terminus, or anterior communicating artery aneurysms\n* Recurring, persistent aneurysm after previous treatment can be included so long as the treating physician judges the aneurysm morphology to be appropriate.\n* Ruptured aneurysms with WFNS ≤ 3\n\nExclusion Criteria:\n\n* Absolute contraindication to surgery, endovascular treatment or anesthesia\n* Patients unable to give informed consent\n* diameter of the aneurysm ≤ 4 mm but ≥ 11 mm\n* Ruptured aneurysms with WFNS 4 or 5",{"count":193,"type":21},250,[24],"Intracranial bifurcation aneurysms are commonly repaired with surgical and with endovascular techniques. Wide-necked bifurcation aneurysms (WNBA) are a difficult subset of aneurysms to successfully repair endovascularly, and a number of treatment adjuncts have been designed. One particularly promising innovation is the WEB (Woven EndoBridge), which permits placement of an intra-saccular flow diverting mesh across the aneurysm neck, but which does not require anti-platelet agent therapy. Currently, which treatment option leads to the best outcome for patients with WNBA remains unknown. There is a need to offer treatment with the WEB within the context of a randomized care trial, to patients currently presenting with aneurysms thought to be suitable for the WEB.",[197,31,198,199,152],"Intracranial Aneurysm","Unruptured Cerebral Aneurysm","Ruptured Cerebral Aneurysm",[69,201,202,203,204,205,206],"cerebral aneurysm","brain aneurysm","unruptured cerebral aneurysm","ruptured cerebral aneurysm","WEB embolization device","embolization","2024-08-13",{"date":209,"type":45},"2024-08-15",{"date":211,"type":45},"2019-07-18",{"date":213,"type":21},"2026-01",{"name":215,"class":83},"Centre hospitalier de l'Université de Montréal (CHUM)",4,{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":224,"sex":17,"minAge":18,"maxAge":117,"enrollmentInfo":225,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":109},"100551186","epidemiological-insights-into-the-formation-progression-and-rupture-of-intracranial-aneurysms-a-retrospective-multi-center-hospital-based-study-in-china-100551186","NCT06456814","Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China","Epidemiological Insights Into the Formation, Progression, and Rupture of Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China","Inclusion Criteria:\n\n1. IA diagnosis (ruptured or unruptured) or exclusion by digital subtractive angiography (DSA) or by cranial computed tomography angiography (CTA) \u002F magnetic resonance angiography (MRA);\n2. Aged ≥ 18 and ≤ 18 years old;\n3. With complete demographic data including age and sex;\n4. With medical record archiving officially.\n\nExclusion Criteria:\n\n1. Missing data of age, sex or hypertensive status;\n2. Age \\\u003C18 or \\>80 years;\n3. Pregnancy;\n4. With a history of intracranial arteriovenous malformation, Moyamoya, polycystic kidney disease, Ehlers-Danlos syndrome, Gronblad-Strandberg syndrome, or Marfan syndrome;\n5. Suspicion for dissecting or mycotic aneurysms or aneurysm-like lesions that were indistinguishable from the infundibulum, fenestration, dilation, or atherosclerotic remodeling on structural imaging scans.",true,{"count":226,"type":21},30000,"This is a retrospective, hospital-based and multi-center study aiming at investigating the potential exposures associated with the formation, progression, and rupture of intracranial aneurysms in Chinese population.",[197,229,152,31],"Subarachnoid Hemorrhage, Aneurysmal",[231,232,233],"Intracranial aneurysm","Clinical epidemiology","Exposures","2024-06-07",{"date":236,"type":45},"2024-06-13",{"date":238,"type":45},"2010-01-01",{"date":240,"type":21},"2026-12-31",{"name":242,"class":83},"Zhujiang Hospital"]